诺泰生物（688076）索赔案持续推进，世纪华通（002602）索赔案再提交法院立案

Group 1 - The core issue involves investor claims against Nuotai Bio (688076) due to false statements leading to ongoing legal proceedings [1][5] - The Shanghai Financial Court has accepted the case for investor claims against Nuotai Bio, with further claims being processed [1][5] - Nuotai Bio's 2021 annual report was found to contain false records, including a reported revenue of 30 million yuan from a technology transfer that lacked commercial substance, inflating total revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported profit [1][5] Group 2 - Investors who purchased Nuotai Bio shares between April 28, 2022, and October 24, 2024, and sold or held shares after October 24, 2024, are eligible to file claims [2][6] - The law firm is also handling claims for Century Huatong (002602), with a recent filing submitted to the Shaoxing Intermediate People's Court [2][6] - Century Huatong was found to have false records in its annual reports from 2018 to 2022, including fabricated software copyright transfer transactions and premature revenue recognition [3][7] Group 3 - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held shares after July 25, 2023, can initiate claims [4][8] - The law firm has a history of successfully representing investors in similar cases, with many having received compensation [4][8]